Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology

Rhea-AI Summary

Klotho Neurosciences (NASDAQ: KLTO) announced plans to expand beyond its core neurology focus to pursue technologies targeting muscle strength, bone health, and longevity indicators. The company is evaluating acquisitions of complementary technologies to support its proprietary anti-aging Klotho platform, while continuing the development of KLTO-101 and KLTO-202.

The expansion focuses on addressing the decline of Klotho levels with age, which contributes to various age-related disorders including cardiometabolic disease, neurodegeneration, cancer, sarcopenia, and osteoporosis. The company is assembling a scientific team to evaluate genes and proteins such as alpha-Klotho, beta-Klotho, FOXO3, and anti-myostatin to develop interventions for age-related diseases.

Positive

• Strategic expansion beyond neurology into broader longevity and anti-aging markets
• Ongoing development of two clinical candidates KLTO-101 and KLTO-202
• Focus on multiple high-value therapeutic areas including cancer, cardiometabolic disease, and bone health
• Strong scientific backing with pleotropic actions of Klotho gene in critical cellular pathways

Negative

• Early-stage expansion with no immediate revenue potential
• Multiple therapeutic areas could strain resources and increase development costs
• No specific timeline or financial details provided for the expansion

Insights

Biotechnology Research Analyst

Klotho's expansion beyond neuroscience into broader longevity applications significantly diversifies their market opportunities while leveraging their existing platform technology.

Klotho Neurosciences is making a strategic pivot to expand beyond its original neurology focus into broader longevity applications. While continuing development of their neurodegenerative disease pipeline (KLTO-101 and KLTO-202), they're now exploring acquisitions in muscle strength, bone health, and other aging-related conditions. This represents a significant market expansion as it opens potential opportunities in multiple age-related conditions beyond the brain.

The scientific rationale is sound—the Klotho gene functions as a pleiotropic regulator affecting multiple aging pathways, including insulin resistance, IGF-1 signaling, FOXO3 transcription, and Wnt signaling. These mechanisms influence inflammation, oxidative stress, and cellular damage across multiple organ systems. The company is specifically targeting alpha-Klotho, beta-Klotho, FOXO3, anti-myostatin, and related isoforms—all well-established longevity targets with scientific validity.

This expansion allows Klotho to diversify risk across multiple indications while leveraging their core expertise in Klotho biology. However, this announcement lacks specifics on timelines, resource allocation, or how this affects their current neurological programs. The transition from a neuroscience-focused company to a broader longevity platform will require careful execution to prevent dilution of their current pipeline efforts. No financial details or specific acquisition targets were disclosed, making it difficult to quantify the near-term impact on operations or balance sheet.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company to Pursue Technologies to Improve Muscle Strength, Bone Health, and Other Longevity Indicators

NEW YORK, July 24, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) (the "Company" or "Klotho") announced today that it is evaluating the acquisition of several complementary technologies aimed at supporting healthy brain function, organ health, and longevity.

In addition to its core programs targeting brain aging and neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's, the Company is now seeking to expand into adjacent technologies that complement its proprietary anti-aging Klotho platform. The goal is to slow biological aging and reduce the burden of age-related diseases—ultimately promoting a longer, healthier life.

"As announced previously, we've begun manufacturing and clinical development of KLTO-101 and KLTO-202," said Klotho CEO Dr. Joseph Sinkule. "We're also exploring other treatments that could support healthy aging and extend human longevity."

The human Klotho gene is strongly linked to aging and longevity. Klotho levels decline with age, contributing to age-related disorders such as cardiometabolic disease, neurodegeneration, cancer, sarcopenia (muscle wasting), osteoporosis, and general fatigue. Silencing of the Klotho gene has been shown to accelerate multi-organ deterioration.

"The Klotho gene is what we call a "master gene" stated Shalom Hirschman, M.D., world renowned physician and senior consultant to KLTO. Dr. Hirschman goes on to say "the Klotho gene has pleotropic actions modulating many critical cellular pathways including insulin resistance, insulin-like growth factor-1, FOXO3 transcription factors, and Wnt signaling pathways leading to the reduction of inflammatory and mitochondrial oxidative stresses and other cell-damaging mechanisms that can be prevented by two α-Klotho protein isoforms – soluble Klotho and secreted-Klotho."

"We're assembling a team of scientists, clinicians, and business leaders focused on identifying key longevity indicators," said Jeffrey LeBlanc, Klotho CFO. "This includes evaluating genes and proteins such as alpha-Klotho, beta-Klotho, FOXO3, anti-myostatin, and their isoforms."

Dr. Sinkule added, "If people don't die of cancer or trauma, they often succumb to age-related diseases of the brain, heart, kidneys, liver, bone, or muscle. Our mission is to identify and develop complementary assets to delay these outcomes through targeted research and intervention."

About Klotho Neurosciences, Inc. Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.

Investor Contact and Corporate Communications - Jeffrey LeBlanc, CFO
ir@klothoneuro.com

Website: www.klothoneuro.com.

Forward-Looking Statements:

This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements.  All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/klotho-neurosciences-inc-to-expand-development-programs-beyond-neurology-302513429.html

SOURCE Klotho Neurosciences, Inc.

FAQ

What is Klotho Neurosciences (KLTO) expanding into beyond neurology?

KLTO is expanding into technologies targeting muscle strength, bone health, and longevity indicators, while evaluating acquisitions of complementary technologies to support its anti-aging Klotho platform.

What are the main drug candidates in Klotho Neurosciences' pipeline?

The company is currently manufacturing and developing two clinical candidates: KLTO-101 and KLTO-202.

How does the Klotho gene affect aging and longevity?

The Klotho gene is a 'master gene' that modulates critical cellular pathways including insulin resistance, insulin-like growth factor-1, FOXO3 transcription factors, and Wnt signaling pathways. Its levels decline with age, contributing to various age-related disorders.

What age-related conditions does Klotho Neurosciences aim to address?

KLTO aims to address multiple age-related conditions including cardiometabolic disease, neurodegeneration, cancer, sarcopenia (muscle wasting), osteoporosis, and general fatigue.

Which proteins and genes is KLTO evaluating for longevity research?

KLTO is evaluating alpha-Klotho, beta-Klotho, FOXO3, anti-myostatin, and their isoforms as key longevity indicators.